OmniAb (OABI) Common Equity (2021 - 2026)
OmniAb (OABI) posted quarterly Common Equity of $262.6 million for Q1 2026, down 3.97% year-over-year from $273.5 million in Q1 2025, and down 1.64% quarter-over-quarter from $267.0 million in Q4 2025.
OmniAb (OABI) Common Equity (2021 - 2026) Analysis & Trends
OmniAb (OABI) has reported Common Equity for 6 consecutive years, with $262.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 3.97% year-over-year to $262.6 million; the TTM figure through Mar 2026 stood at $262.6 million (down 3.97% YoY), while the FY2025 annual figure was $267.0 million, down 7.16% from the prior year.
- Common Equity declined to $262.6 million in Q1 2026 per OABI's latest filing, from $267.0 million in the prior quarter.
- Across five years, Common Equity topped out at $341.4 million in Q4 2022 and bottomed at $224.9 million in Q1 2022.
- Historically, Common Equity has averaged $285.7 million across 5 years, with a median of $287.6 million in 2024.
- Annual changes were most pronounced in 2022 — Common Equity soared 1509933.93% — and 2024, when it dropped 11.87%.
- OmniAb's Common Equity stood at $341.4 million in 2022, then dropped by 7.85% to $314.6 million in 2023, then retreated by 8.57% to $287.6 million in 2024, then dropped by 7.16% to $267.0 million in 2025, then decreased by 1.64% to $262.6 million in 2026.
- Business Quant data shows OABI's Common Equity at $262.6 million in Q1 2026, $267.0 million in Q4 2025, and $277.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn | 260.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 260.27 Mn |
| Mar 31, 2026 | 262.65 Mn |
| Dec 31, 2025 | 267.03 Mn |
| Sep 30, 2025 | 277.44 Mn |
| Jun 30, 2025 | 262.06 Mn |
| Mar 31, 2025 | 273.52 Mn |
| Dec 31, 2024 | 287.62 Mn |
| Sep 30, 2024 | 291.73 Mn |
| Jun 30, 2024 | 294.18 Mn |
| Mar 31, 2024 | 301.39 Mn |
| Dec 31, 2023 | 314.59 Mn |
| Sep 30, 2023 | 324.55 Mn |
| Jun 30, 2023 | 333.81 Mn |
| Mar 31, 2023 | 340.80 Mn |
| Dec 31, 2022 | 341.37 Mn |
| Sep 30, 2022 | 232.71 Mn |
| Jun 30, 2022 | 226.94 Mn |
| Mar 31, 2022 | 224.92 Mn |
| Dec 31, 2021 | 234.31 Mn |
| Sep 30, 2021 | -6.90 Mn |